Intranasal zaleplon abuse

American Journal of Psychiatry

Volumn 165, Issue 11, 2008, Pages 1489-1490

  Paparrigopoulos, Thomas ^a   Tzavellas, Elias ^a   Karaiskos, Dimitris ^a   Liappas, Ioannis ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ZALEPLON;

ADULT; BEDTIME DOSAGE; CASE REPORT; CLINICAL FEATURE; DRUG ABUSE; DRUG EFFECT; EUPHORIA; HUMAN; LETTER; MALE; PRIORITY JOURNAL; SLEEP DISORDER; SYMPTOM; WITHDRAWAL SYNDROME;

ACETAMIDES; ADMINISTRATION, INTRANASAL; ADULT; AFFECT; DOSE-RESPONSE RELATIONSHIP, DRUG; EUPHORIA; HUMANS; HYPNOTICS AND SEDATIVES; MALE; PYRIMIDINES; RISK FACTORS; SLEEP INITIATION AND MAINTENANCE DISORDERS; SUBSTANCE-RELATED DISORDERS;

EID: 55749090992     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2008.08030452     Document Type: Letter

References (5)

1. Griffiths RR, Johnson MW: Relative abuse liability of hypnotic drugs: a conceptual framework and algorithm for differentiating among compounds. J Clin Psychiatry 2005; 66:31-41
2. Rush CR, Frey JM, Griffiths RR: Zaleplon and triazolam in humans: acute behavioral effects and abuse potential. Psychopharmacology (Berl) 1999; 145:39-51
3. Ator NA, Weerts EM, Kaminski BJ, Kautz MA, Griffiths RR: Zaleplon and triazolam physical dependence assessed across increasing doses under a once-daily dosing regimen in baboons. Drug Alcohol Depend 2000; 61:69-84
4. A receptor gene expression induced by withdrawal of, but not by long-term exposure to, zaleplon or zolpidem. Neuropharmacology 2002; 42:191-198
5. Goodman A: Neurobiology of addiction: an integrative review. Biochem Pharmacol 2008; 75:266-322